MET and neoplasm: Because MET is a target antigen that is expressed in many tumor types but also found in healthy tissues, leveraging MET targeting ADCs serves as a platform for interrogating the role that the target binding affinity of the antibody component of ADCs can have on the therapeutic window of these modalities (Fig 1).